Clinical parameter | n (% ) | Median (months) | P value |
---|---|---|---|
Age | Â | Â | 0.5287 |
o < 65 | 60 (81.1%) | 41.8 | Â |
o > 65 | 14 (18.9%) | 36.6 | |
FIGO stage at diagnosis | Â | Â | Â |
o Early (I,II) | 15 (20.3%) | 88.2%†| 0.0168* |
o Advanced (III,IV) | 59 (79.7%) | 50.5%†| |
Histopathologic cell type | Â | Â | Â |
o serous | 37 (50%) | 33.4 | 0.0166* |
o others | 37 (50%) | 54.8 | |
Residual tumor size | Â | Â | Â |
o <1 cm | 48 (64.9%) | 50.2 | 0.0026* |
o > 1 cm | 26 (35.1%) | 22.6 | |
Performance status (ECOG) | Â | Â | Â |
o 0-1 | 69 (93.2%) | 42.9 | 0.3461 |
o 5 (6.7%) | 5 (6.7%) | 15.1 | |
Tumor grade | Â | Â | Â |
o G1,G2 | 31 (41.9%) | 49.0 | 0.2099 |
o G3, unknown | 43 (58.1%) | 30.0 | |
Sensitivity to first-line chemotherapy | Â | Â | Â |
o Resistant (<6 months) | 26 (35.1%) | 4.6%†| <0.0001* |
o Sensitive (>6 months) | 48 (64.9%) | 87.8%†| |
Tau expression | Â | Â | Â |
o negative | 19(25.6%) | 80.2%†| 0.0198* |
o positive | 55(79.3%) | 52.4%†|